Related Experiment Video
Updated: Feb 15, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
SATB1 is a Novel Molecular Target for Cancer Therapy
Meng Ding1,2, Jun Pan1,2, Zhicheng Guo2
1a Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou University , Xuzhou , China.
Abstract:
The special AT-rich sequence binding-protein1 (SATB1) attracts excessive attention due to its high expression in a variety of malignancies. SATB1 reprograms chromatin and transcription profiles to promote tumor cell growth and invasion and inhibit apoptosis, leading to tumor progression and metastasis. Consistently, silencing SATB1 with small interfering RNA inhibits the growth and invasion of some kinds of tumors. In this review, we highlight recent progress in our understanding of the role of SATB1 as global regulator of gene expression during cancer development, and evaluate the potential of SATB1 as a molecular therapeutic target for cancers with aberrant SATB1 expression.
Insights
Special AT-rich sequence binding-protein1 (SATB1) promotes cancer progression and metastasis. Silencing SATB1 inhibits tumor growth, highlighting its potential as a therapeutic target for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Special AT-rich sequence binding-protein1 (SATB1) is frequently overexpressed in numerous cancers.
- SATB1 plays a critical role in reprogramming cellular processes that drive tumor development.
Purpose of the Study:
- To review the role of SATB1 in regulating gene expression during cancer.
- To evaluate SATB1 as a potential therapeutic target for cancer treatment.
Main Methods:
- Literature review of recent studies on SATB1 in cancer.
- Analysis of SATB1's function in chromatin remodeling and gene transcription.
- Assessment of SATB1's impact on tumor cell growth, invasion, and apoptosis.
Main Results:
- SATB1 overexpression promotes tumor cell growth, invasion, and metastasis.
- SATB1 aberrant expression is linked to tumor progression.
- Inhibition of SATB1 via small interfering RNA reduces tumor growth and invasion in certain cancers.
Conclusions:
- SATB1 is a global regulator of gene expression crucial for cancer development.
- Targeting SATB1 presents a promising therapeutic strategy for cancers exhibiting abnormal SATB1 expression.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Gene Therapy
Molecular Models
Molecular Orbital Theory II
Molecular Orbital Theory I

